Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist

Documenti analoghi

• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  di: Faisal I. Almohaileb, et al.
  Pubblicazione: (2025)
• Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
  di: Mona Abdel‐Bary, et al.
  Pubblicazione: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  di: Darren Lau, et al.
  Pubblicazione: (2024)
• Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
  di: Jason M. Samuels, et al.
  Pubblicazione: (2024)